Encephalomyelitis

GC Biopharma to Present New Data on Trends in Varicella Incidence Cases with Complications Among Korean Children at the 2022 ICPE

Retrieved on: 
Wednesday, August 24, 2022
Biotechnology, Infectious Diseases, Other Health, Health, Pharmaceutical, ICPE, Vaccination, Ageing, Green Cross, Vaccine, Pneumonia, Encephalomyelitis, Incidence, Person, Encephalitis, Knowledge Organization (journal), Department, Doctor of Science, Chickenpox, Conference, Therapy, GC, 2021 Essex County Council election, Biopharma LLC, Meningitis, International Conference of Physics Students, Myelitis, Research

GC Biopharma (006280.KS) today announced that it will present new data demonstrating trends in the incidence of varicella cases with complications among Korean children during 2010-2020 after the universal one-dose varicella vaccination program.

Key Points: 
  • GC Biopharma (006280.KS) today announced that it will present new data demonstrating trends in the incidence of varicella cases with complications among Korean children during 2010-2020 after the universal one-dose varicella vaccination program.
  • The results show that varicella incidence cases with complications among Korean children significantly (92%) decreased from 137 per 100,000 persons in 2010 to 11 per 100,000 persons in 2020.
  • In the sub-analyses, the decrease in the incidence of varicella cases with complications was greater in children aged 0-4 (96%) and aged 5-9 (92%) than in children aged 10-19 (77-78%).
  • In addition, this study indicates that the universal one-dose varicella vaccination program introduced in 2005 has been successful in preventing severe incident varicella cases among Korean children.

Nearly $100M in Long COVID Funding Introduced in Congress

Retrieved on: 
Thursday, May 27, 2021
Chronic fatigue syndrome, Medicine, Organ systems, Branches of biology, Long Covid, Encephalomyelitis, Me, Action for ME, Controversies related to chronic fatigue syndrome

and the Long COVID Alliance has been instrumental in getting us to this critical juncture," said Representative Don Beyer (D-VA).

Key Points: 
  • and the Long COVID Alliance has been instrumental in getting us to this critical juncture," said Representative Don Beyer (D-VA).
  • While2.5 million Americans currently suffer from Myalgic Encephalomyelitis, Chronic Fatigue Syndrome (ME/CFS) and Long COVID, experts estimate two-fold growthas a result of the pandemic.
  • The COVID-19 Long Haulers Act was introduced following the 5th Annual ME/CFS Advocacy Week hosted by the Solve M.E.
  • During the weeklong event, three members of Congress and a record number of participants held nearly 350 congressional meetingspushing for more funding and support.

Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells

Retrieved on: 
Wednesday, October 21, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Branches of biology, Nervous system, Neuroscience, Central nervous system disorders, Autoimmune diseases, Myelitis, Experimental autoimmune encephalomyelitis, Encephalomyelitis, Neuritis, Nerve, Spinal cord, Optic nerve

These new, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.

Key Points: 
  • These new, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.
  • All mice were sacrificed on day 42 post-immunization, and optic nerves and spinal cords were collected for analyses.
  • The hypothesis was that the cells would continue to secrete the secretome in vivo, thus acting like a delivery system.
  • We are pleased to see these preclinical results for the treatment of damaged optic nerves and spinal cord myelitis using systemically administered AMP cells.

Global Encephalomyelitis Pipeline Review 2020: Therapeutic Analysis Report Featuring 7 Companies & 5 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 13, 2020
Biotechnology, Pharmaceutical, Health, Encephalomyelitis

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.

Key Points: 
  • The Encephalomyelitis (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Solve M.E. Announces Oved Amitay as President and Chief Executive Officer

Retrieved on: 
Thursday, May 21, 2020
Organ systems, Medicine, Medical specialties, Solve ME/CFS Initiative, Chronic fatigue syndrome, Encephalomyelitis, Action for ME

, the leading, national non-profit organization solely dedicated to solving Myalgic Encephalomyelitis, formerly known as Chronic Fatigue Syndrome (ME/CFS), today announced that Oved Amitay has been named as President and Chief Executive Officer as of June 1, 2020.

Key Points: 
  • , the leading, national non-profit organization solely dedicated to solving Myalgic Encephalomyelitis, formerly known as Chronic Fatigue Syndrome (ME/CFS), today announced that Oved Amitay has been named as President and Chief Executive Officer as of June 1, 2020.
  • Maryellen Gleason, who has been acting as Interim President and CEO of Solve M.E.
  • "We could not be more pleased to welcome Oved," said John Nicols, Solve M.E.
  • A link to Oved Amitay's full bio can be found here: Oved Amitay Bio
    To learn more about the Solve ME/CFS Initiative, visit www.solvecfs.org .

Solve M.E. Announces Oved Amitay as President and Chief Executive Officer

Retrieved on: 
Thursday, May 21, 2020
Organ systems, Medicine, Medical specialties, Solve ME/CFS Initiative, Chronic fatigue syndrome, Encephalomyelitis, Action for ME

, the leading, national non-profit organization solely dedicated to solving Myalgic Encephalomyelitis, formerly known as Chronic Fatigue Syndrome (ME/CFS), today announced that Oved Amitay has been named as President and Chief Executive Officer as of June 1, 2020.

Key Points: 
  • , the leading, national non-profit organization solely dedicated to solving Myalgic Encephalomyelitis, formerly known as Chronic Fatigue Syndrome (ME/CFS), today announced that Oved Amitay has been named as President and Chief Executive Officer as of June 1, 2020.
  • Maryellen Gleason, who has been acting as Interim President and CEO of Solve M.E.
  • "We could not be more pleased to welcome Oved," said John Nicols, Solve M.E.
  • A link to Oved Amitay's full bio can be found here: Oved Amitay Bio
    To learn more about the Solve ME/CFS Initiative, visit www.solvecfs.org .

JOGO Health Launches COVID-19 Chronic Fatigue Syndrome Study

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Organ systems, Health, Chronic fatigue syndrome, Solve ME/CFS Initiative, Encephalomyelitis, Fatigue, Post-exertional malaise, Action for ME

BRIDGEWATER, N.J., May 13, 2020 /PRNewswire/ -- JOGOHEALTH Inc., a Bridgewater, New Jersey based privately held digital therapeutics company focused on the development and commercialization oftreatments for neuromuscular (NM) and chronic pain conditions today announced that it will launch a study on COVID-19 related Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).

Key Points: 
  • BRIDGEWATER, N.J., May 13, 2020 /PRNewswire/ -- JOGOHEALTH Inc., a Bridgewater, New Jersey based privately held digital therapeutics company focused on the development and commercialization oftreatments for neuromuscular (NM) and chronic pain conditions today announced that it will launch a study on COVID-19 related Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).
  • According to the patient advocacy group Solve ME/CFS Initiative, nearly 35% of COVID-19 patients are experiencing ME/CFS symptoms post infection.
  • Since the onset of ME/CFS usually follows a viral infection, experts estimate up to 3,570,000 new ME/CFS cases following the COVID-19 pandemic.
  • "The science behind JOGO has shown to work for Fibromyalgia in many peer reviewed studies.

Endonovo Therapeutics Announces Issuance of Broad Patent Covering Electromagnetic Treatment of Multiple Sclerosis

Retrieved on: 
Tuesday, January 14, 2020
Intellectual property law, Encephalomyelitis, EAE, United States Patent and Trademark Office, Multiple sclerosis

Los Angeles, CA, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent for Application No.

Key Points: 
  • Los Angeles, CA, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent for Application No.
  • 15/549,748 covering method and apparatus for electromagnetic treatment of multiple sclerosis.
  • Our preliminary research in the field of Autoimmune Encephalomyelitis - the inflammatory autoimmune model of multiple sclerosis, reveals significant change in the EAE score of treated animals when compared to sham.
  • Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices.

Encephalomyelitis - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 22, 2019
Health, Pharmaceutical, Encephalomyelitis

The "Encephalomyelitis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Encephalomyelitis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Radiation Model for Chronic Fatigue Syndrome Announced by the National CFIDS Foundation

Retrieved on: 
Monday, May 20, 2019
Chronic fatigue syndrome, Branches of biology, Medicine, Organ systems, Encephalomyelitis, Cardiolipin, Myelitis, Mitochondrion, Fatigue, David Sheffield Bell, Solve ME/CFS Initiative

NEEDHAM, Mass., May 20, 2019 /PRNewswire/ --The National CFIDS Foundation, of Needham, Massachusetts, has provided details regarding its radiation model for Chronic Fatigue Syndrome, a disease that affects millions in the United States.

Key Points: 
  • NEEDHAM, Mass., May 20, 2019 /PRNewswire/ --The National CFIDS Foundation, of Needham, Massachusetts, has provided details regarding its radiation model for Chronic Fatigue Syndrome, a disease that affects millions in the United States.
  • According to Alan Cocchetto, Medical Director for the National CFIDS Foundation, "Our latest model has now identified two key compounds, known as hydroperoxides, that appear to result from cellular injury due to radiation exposure.
  • The National CFIDS Foundation identified cardiolipin hydroperoxides as the first key target that acts to disrupt proper functioning of the mitochondria, the energy factory within the cell.
  • According to the National CFIDS Foundation, Chronic Fatigue Syndrome (CFS) is also known as Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) as well as Myalgic Encephalomyelitis (ME).